165 related articles for article (PubMed ID: 11021614)
1. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates.
Tarone RE; Chu KC; Brawley OW
Epidemiology; 2000 Mar; 11(2):167-70. PubMed ID: 11021614
[TBL] [Abstract][Full Text] [Related]
2. Trends in prostate cancer mortality among black men and white men in the United States.
Chu KC; Tarone RE; Freeman HP
Cancer; 2003 Mar; 97(6):1507-16. PubMed ID: 12627516
[TBL] [Abstract][Full Text] [Related]
3. Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.
Hankey BF; Feuer EJ; Clegg LX; Hayes RB; Legler JM; Prorok PC; Ries LA; Merrill RM; Kaplan RS
J Natl Cancer Inst; 1999 Jun; 91(12):1017-24. PubMed ID: 10379964
[TBL] [Abstract][Full Text] [Related]
4. Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality.
Etzioni R; Legler JM; Feuer EJ; Merrill RM; Cronin KA; Hankey BF
J Natl Cancer Inst; 1999 Jun; 91(12):1033-9. PubMed ID: 10379966
[TBL] [Abstract][Full Text] [Related]
5. Trends in the stage specific incidence of prostate carcinoma in the Detroit metropolitan area, 1973-1994.
Schwartz KL; Severson RK; Gurney JG; Montie JE
Cancer; 1996 Sep; 78(6):1260-6. PubMed ID: 8826949
[TBL] [Abstract][Full Text] [Related]
6. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.
Jemal A; Fedewa SA; Ma J; Siegel R; Lin CC; Brawley O; Ward EM
JAMA; 2015 Nov; 314(19):2054-61. PubMed ID: 26575061
[TBL] [Abstract][Full Text] [Related]
7. The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States.
Legler JM; Feuer EJ; Potosky AL; Merrill RM; Kramer BS
Cancer Causes Control; 1998 Oct; 9(5):519-27. PubMed ID: 9934717
[TBL] [Abstract][Full Text] [Related]
8. A prospective study of the serum prostate specific antigen concentrations and Gleason histologic scores of black and white men with prostate carcinoma.
Fowler JE; Bigler SA
Cancer; 1999 Sep; 86(5):836-41. PubMed ID: 10463983
[TBL] [Abstract][Full Text] [Related]
9. The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States.
Howrey BT; Kuo YF; Lin YL; Goodwin JS
J Gerontol A Biol Sci Med Sci; 2013 Jan; 68(1):56-61. PubMed ID: 22562961
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.
Moul JW; Sesterhenn IA; Connelly RR; Douglas T; Srivastava S; Mostofi FK; McLeod DG
JAMA; 1995 Oct; 274(16):1277-81. PubMed ID: 7563532
[TBL] [Abstract][Full Text] [Related]
11. Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men.
Smith DS; Carvalhal GF; Mager DE; Bullock AD; Catalona WJ
J Urol; 1998 Nov; 160(5):1734-8. PubMed ID: 9783942
[TBL] [Abstract][Full Text] [Related]
12. Prospective study of cancer detection in black and white men with normal digital rectal examination but prostate specific antigen equal or greater than 4.0 ng/mL.
Fowler JE; Bigler SA; Farabaugh PB
Cancer; 2002 Mar; 94(6):1661-7. PubMed ID: 11920526
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer incidence, mortality, and survival trends in the United States: 1981-2001.
Sarma AV; Schottenfeld D
Semin Urol Oncol; 2002 Feb; 20(1):3-9. PubMed ID: 11828352
[TBL] [Abstract][Full Text] [Related]
14. Screening for prostate cancer: updated experience from the Tyrol study.
Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
[TBL] [Abstract][Full Text] [Related]
15. Trends in Prostate Specific Antigen (PSA) testing and prostate cancer incidence and mortality in Australia: A critical analysis.
Pathirana T; Sequeira R; Del Mar C; Dickinson JA; Armstrong BK; Bell KJL; Glasziou P
Cancer Epidemiol; 2022 Apr; 77():102093. PubMed ID: 35026706
[TBL] [Abstract][Full Text] [Related]
16. Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL.
Ang M; Rajcic B; Foreman D; Moretti K; O'Callaghan ME
BJU Int; 2016 Apr; 117 Suppl 4():68-75. PubMed ID: 26890320
[TBL] [Abstract][Full Text] [Related]
17. Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer.
Moore AL; Dimitropoulou P; Lane A; Powell PH; Greenberg DC; Brown CH; Donovan JL; Hamdy FC; Martin RM; Neal DE
BJU Int; 2009 Dec; 104(11):1592-8. PubMed ID: 19549125
[TBL] [Abstract][Full Text] [Related]
18. Percent free prostate specific antigen and cancer detection in black and white men with total prostate specific antigen 2.5 to 9.9 ng./ml.
Fowler JE; Sanders J; Bigler SA; Rigdon J; Kilambi NK; Land SA
J Urol; 2000 May; 163(5):1467-70. PubMed ID: 10751859
[TBL] [Abstract][Full Text] [Related]
19. Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates.
Feuer EJ; Mariotto A; Merrill R
Cancer; 2002 Aug; 95(4):870-80. PubMed ID: 12209732
[TBL] [Abstract][Full Text] [Related]
20. Comparison of prostate-specific antigen and hormone levels among men in Singapore and the United States.
Cheng I; Yu MC; Koh WP; Pike MC; Kolonel LN; Henderson BE; Stram DO
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1692-6. PubMed ID: 16030103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]